ViewRay this morning preannounced better than expected Q3 sales results after installing three systems compared to the Street estimate at two, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Further, the eight MRIdian system orders in Q3, including three upgrades, were in-line with expectations and a "welcome sight" as investors had worried that hesitancy around the proposed reimbursement bundle would result in significant delays in purchasing decisions, adds the analyst. He views the results as "largely positive" and reiterates an Overweight rating on ViewRay shares with a $6 price target. O'Brien, who admits the company's cash burn was a little higher than he had modeled, sees a "compelling entry point" at current ViewRay share levels.